Search

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

Meeting program

EHA ReCon 2025



Read more

Meeting Program

EHA-HKSH Hematology Tutorial 2025



Read more

Research training documents for scholars

CBTH documentsCBTH Non-disclosure Agreement

CRTH documentsCRTH Conditions of Acceptance and Participation

CRTH Non-disclosure Agreement

TRTH documentsTRTH Non-disclosure Agreement

Read more

Meeting Program

EHA-SWG Secondary AML - April 2025



Read more

Register for EHA2025

Get ready to make new connections in Milan from June 12–15, 2025. Register now for EHA's reimagined Congress experience.

Read more